Press Releases

CRANBURY, N.J., Sept. 7, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that its collaboration partner,  AstraZeneca, has decided to discontinue further development of AZD2820, one of a number of collaboration compounds in various stages of development for the treatment of obesity.  AstraZeneca remains committed to this collaboration program and to the continued […]

CRANBURY, N.J., Sept.  6, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter, fiscal year 2012 financial results on Tuesday, September 11, 2012 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 11,

CRANBURY, N.J., July 2, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that it has entered into a definitive securities agreement and priced a private placement of 3,873,000 shares of its common stock, Series A warrants to purchase 31,988,151 shares of its common stock, and Series B warrants to purchase 35,488,380 shares of

CRANBURY, N.J., June 19, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that a Phase I clinical trial being conducted by AstraZeneca of AZD2820, a subcutaneously-administered peptide melanocortin-4 receptor partial agonist under development for the treatment of obesity, has been halted. AZD2820 is a clinical candidate under development by AstraZeneca from a collaborative

CRANBURY, N.J., May 14, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2012.  Palatin reported a net loss of $6.0 million, or $(0.17) per

CRANBURY, N.J., May 8, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its third quarter, fiscal year 2012 financial results on Monday, May 14, 2012 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May

CRANBURY, N.J., March 8, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) today announced it has completed enrollment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).  Over 400 premenopausal women, diagnosed with female sexual arousal disorder, hypoactive sexual desire disorder or both, have

CRANBURY, N.J., March 7, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the 24th Annual ROTH OC Growth Stock Conference on Tuesday, March 13, 2012, at 1:30 p.m. Pacific Time.  The conference will be held at the Ritz Carlton Laguna Niguel in Dana Point, CA. Carl Spana,

CRANBURY, N.J., Feb. 15, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2011.  Palatin reported a net loss of $2.6 million, or $(0.08)

CRANBURY, N.J., Feb. 9, 2012 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012 at 8:30 a.m. ET.  Hosted by the Biotechnology Industry Organization (BIO), the 14th Annual BIO CEO & Investor Conference will take place